STAT+: A possible comeback for a failed sickle cell gene therapy

Coverage, in order

1. 6d ago
   
   STAT Biotech indie study

   STAT+: A possible comeback for a failed sickle cell gene therapy

   Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The news is newsing hard these days, no? China hits the brakes on controversial trials China’s fast, cheap route to human testing is getting considerably less speedy. New…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.